Education
About Us
Working with TipRanks
Follow Us
Mesoblast Limited (MEOBF)
:MEOBF
MEOBF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.17 - $5.34
Previous CloseN/A
Volume20.00
Average Volume (3M)151.86K
Market Cap
$1.79B
Enterprise ValueN/A
Total Cash (Recent Filing)$80.93M
Total Debt (Recent Filing)$94.30M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
May 28, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,270,527,200
10 Day Avg. Volume14
30 Day Avg. Volume151,859
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)24.95
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.11Price Target Upside54.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Mesoblast Limited News
PremiumCompany Announcements
Mesoblast’s Ryoncil Gains Comprehensive U.S. Drug Pricing Compendia Inclusion
PremiumCompany Announcements
Mesoblast Unveils First FDA-Approved Stem Cell Therapy
PremiumCompany Announcements
Mesoblast Director Increases Stake with ADS Acquisition
PremiumCompany Announcements
Mesoblast Joins S&P/ASX 200 Index, Marking Growth Milestone
PremiumCompany Announcements
Mesoblast Limited Joins S&P/ASX 200 Index---
Ownership Overview
20.51% Insiders
2.43% Mutual Funds
0.01% Other Institutional Investors
74.69% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
MEOBF FAQ
What was Mesoblast Limited’s price range in the past 12 months?
Mesoblast Limited lowest stock price was $0.17 and its highest was $5.34 in the past 12 months.
What is Mesoblast Limited’s market cap?
Mesoblast Limited’s market cap is $1.79B.
When is Mesoblast Limited’s upcoming earnings report date?
Mesoblast Limited’s upcoming earnings report date is May 28, 2025 which is in 64 days.
How were Mesoblast Limited’s earnings last quarter?
Mesoblast Limited released its earnings results on Feb 26, 2025. The company reported -$0.042 earnings per share for the quarter, missing the consensus estimate of -$0.028 by -$0.014.
Is Mesoblast Limited overvalued?
According to Wall Street analysts Mesoblast Limited’s price is currently Undervalued.
Does Mesoblast Limited pay dividends?
Mesoblast Limited does not currently pay dividends.
What is Mesoblast Limited’s EPS estimate?
Mesoblast Limited’s EPS estimate is -0.01.
How many shares outstanding does Mesoblast Limited have?
Mesoblast Limited has 1,270,527,200 shares outstanding.
What happened to Mesoblast Limited’s price movement after its last earnings report?
Mesoblast Limited reported an EPS of -$0.042 in its last earnings report, missing expectations of -$0.028. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mesoblast Limited?
Currently, no hedge funds are holding shares in MEOBF
---
Mesoblast Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.11 (54.01% Upside)
$2.11 (54.01% Upside)
Blogger Sentiment
Bullish
MEOBF Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $17.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
528.44%
12-Months-Change
Fundamentals
Return on Equity
-21.31%
Trailing 12-Months
Asset Growth
-2.53%
Trailing 12-Months
Company Description
Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
---
MEOBF Company Deck
---
MEOBF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements, including the FDA approval of a key product and successful fundraising, alongside a strategic pipeline expansion. However, financial losses and dependency on future regulatory approvals present challenges. Overall, the sentiment reflects a positive outlook with caution about future regulatory and financial hurdles.Read More>---
MEOBF Stock 12 Month Forecast
Average Price Target
$2.11
▲(54.01% Upside)
Technical Analysis
Biotron Limited
―
Cochlear Limited
―
Cynata Therapeutics Limited
―
Nanosonics Limited
―
Immutep Ltd
―
Best Analysts Covering MEOBF
1 Year
1 Year Success Rate
2/9 ratings generated profit
1 Year Average Return
-21.09%
reiterated a buy rating 26 days ago
Copying John Hester's trades and holding each position for 1 Year would result in 22.22% of your transactions generating a profit, with an average return of -21.09% per trade.
---